CPHI report predicts huge funding overhang to drive contract services growth1 November 2022 | By European Pharmaceutical ReviewPrivate equity overhang to fuel CDMO valuations and expansions, while venture capital overhang will fuel continued demand for services in spite of adverse global conditions.
Biopharma successful in achieving climate-related goals, report finds31 October 2022 | By Catherine Eckford (European Pharmaceutical Review)A report shows two Big Pharma companies made the top 10 in the FTSE sustainability leaderboard, yet progress against climate goals has stalled since COP26.
EMA’s PRAC confirms recommendation to withdraw amfepramones31 October 2022 | By Catherine Eckford (European Pharmaceutical Review)The EMA’s safety board verifies that amfepramone-containing products for obesity should not be sold, due to higher-associated health risks.
EMA validates AbbVie lymphoma bispecific antibody application31 October 2022 | By Catherine Eckford (European Pharmaceutical Review)AbbVie's marketing application for epcoritamab in adults with relapsed/refractory diffuse large B-cell lymphoma has been validated by the European Medicines Agency.
Outsourcing APIs put EU patients at risk28 October 2022 | By Catherine Eckford (European Pharmaceutical Review)Teva warns APIs could disappear from European factories in five to 10 years if the industry does not see outsourcing essential medicine manufacture as risky.
First patient receives new engineered mRNA epigenetic28 October 2022 | By Catherine Eckford (European Pharmaceutical Review)OTX-2002, a programmable epigenetic medicine is the first mRNA therapy to target MYC dysregulation and could treat hepatocellular carcinoma.
CPHI report predicts biologics outsourcing to surge in 202327 October 2022 | By European Pharmaceutical ReviewReport out ahead of CPHI Frankfurt predicts ‘biologics outsourcing to surge in 2023, as China’s innovation engine stalls.'
Astellas invests $50 million in Taysha Gene Therapies27 October 2022 | By Catherine Eckford (European Pharmaceutical Review)Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
$3 trillion growth reported for biotech sector27 October 2022 | By Catherine Eckford (European Pharmaceutical Review)A report reveals US job growth in the biotech industry has risen 11 percent since 2018, tipping the COVID-19 pandemic as the key driver.
NICE recommends first oral GnRH antagonist for uterine fibroids26 October 2022 | By Catherine Eckford (European Pharmaceutical Review)Ryeqo, a one-per-day oral drug for adults with moderate-to-severe symptoms of uterine fibroids has been given the green light by NICE.
University of Oklahoma to open bioprocessing training facility26 October 2022 | By Catherine Eckford (European Pharmaceutical Review)The centre will help prepare engineers and advance research in this emerging industry, according to Gallogly College of Engineering’s Associate Dean for Research.
ITM licenses targeted radionuclide therapy candidate26 October 2022 | By Catherine Eckford (European Pharmaceutical Review)The targeted radionuclide therapy for glioblastoma is administered into a tumour cavity via a reservoir post-surgery and standard post-operative therapy.
ADC developers opt to outsource26 October 2022 | By Caroline Peachey (European Pharmaceutical Review)Most developers of antibody drug conjugates choose to outsource operations to mitigate manufacturing challenges, says report.
AstraZeneca dual immunotherapy approved for US liver cancer patients25 October 2022 | By Catherine Eckford (European Pharmaceutical Review)The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
Vaccine producers promise equal access in future pandemics24 October 2022 | By Catherine Eckford (European Pharmaceutical Review)COVID-19 vaccine key players back a new proposal ensuring vaccines for future pandemics are equally distributed to all priority populations.
